TWI918610B - 作為klk5/7雙重抑制劑之苯并酮化合物 - Google Patents

作為klk5/7雙重抑制劑之苯并酮化合物

Info

Publication number
TWI918610B
TWI918610B TW109134275A TW109134275A TWI918610B TW I918610 B TWI918610 B TW I918610B TW 109134275 A TW109134275 A TW 109134275A TW 109134275 A TW109134275 A TW 109134275A TW I918610 B TWI918610 B TW I918610B
Authority
TW
Taiwan
Prior art keywords
compound
approximately
skin
pharmaceutically acceptable
ppm
Prior art date
Application number
TW109134275A
Other languages
English (en)
Chinese (zh)
Other versions
TW202126631A (zh
Inventor
安德亞斯 貝茲
羅伯特 贊博尼
Original Assignee
美商分子皮膚療法公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商分子皮膚療法公司 filed Critical 美商分子皮膚療法公司
Publication of TW202126631A publication Critical patent/TW202126631A/zh
Application granted granted Critical
Publication of TWI918610B publication Critical patent/TWI918610B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
TW109134275A 2019-10-01 2020-09-30 作為klk5/7雙重抑制劑之苯并酮化合物 TWI918610B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
US62/909,006 2019-10-01

Publications (2)

Publication Number Publication Date
TW202126631A TW202126631A (zh) 2021-07-16
TWI918610B true TWI918610B (zh) 2026-03-21

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109134275A TWI918610B (zh) 2019-10-01 2020-09-30 作為klk5/7雙重抑制劑之苯并酮化合物

Country Status (13)

Country Link
US (2) US11643420B2 (enExample)
EP (1) EP4037687B1 (enExample)
JP (1) JP7854389B2 (enExample)
KR (1) KR102994600B1 (enExample)
CN (1) CN114615984B (enExample)
AU (1) AU2020359526B2 (enExample)
BR (1) BR112022005881A2 (enExample)
CA (1) CA3151626A1 (enExample)
ES (1) ES3053975T3 (enExample)
IL (1) IL291398B2 (enExample)
MX (1) MX2022003929A (enExample)
TW (1) TWI918610B (enExample)
WO (1) WO2021067335A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DE4134770A1 (de) 1991-10-22 1993-04-29 Basf Ag Koernige bleichaktivatorzusammensetzung
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2184851A1 (en) 1996-09-05 1998-03-06 Cheng Chung Wu Method of manufacturing a microweavable flatware article made of synthetic material, the article produced thereby and an ink-imprinted film component for use in making the flatware article
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
HUP0101699A3 (en) 1998-03-31 2002-05-28 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors and pharmaceutical compositions containing the same
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN101152185B (zh) 2003-06-06 2010-12-08 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途
DK3097085T3 (da) * 2014-01-23 2020-10-26 Sixera Pharma Ab Benzoxazinonderivater til behandling af hudsygdomme
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.

Also Published As

Publication number Publication date
MX2022003929A (es) 2022-06-14
TW202126631A (zh) 2021-07-16
AU2020359526B2 (en) 2026-07-16
IL291398B1 (en) 2025-01-01
US12281123B2 (en) 2025-04-22
IL291398A (en) 2022-05-01
ES3053975T3 (en) 2026-01-28
US20210101911A1 (en) 2021-04-08
KR102994600B1 (ko) 2026-07-22
US11643420B2 (en) 2023-05-09
US20240067658A1 (en) 2024-02-29
CN114615984A (zh) 2022-06-10
CA3151626A1 (en) 2021-04-08
EP4037687A4 (en) 2023-09-27
JP7854389B2 (ja) 2026-05-01
EP4037687A1 (en) 2022-08-10
AU2020359526A1 (en) 2022-04-21
KR20220091488A (ko) 2022-06-30
BR112022005881A2 (pt) 2022-06-21
WO2021067335A1 (en) 2021-04-08
JP2022551583A (ja) 2022-12-12
EP4037687B1 (en) 2025-10-29
IL291398B2 (en) 2025-05-01
CN114615984B (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
KR101398648B1 (ko) 리팍시민 직장 기능장애 치료 제제
EP3019166B1 (en) A pharmaceutical combination for the treatment of melanoma
US20130189242A1 (en) Hyaluronidase and Method of use Thereof
JP7854389B2 (ja) Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
CN111848832A (zh) 含氟化合物修饰的阳离子聚合物作为药物载体的应用及制备方法
MX2008003882A (es) Formulacion de capsula de pirfenidona y excipientes farmaceuticamente aceptables.
JP2020520995A (ja) 皮膚障害の処置用のピロロピリジン−アニリン化合物
US20250179062A1 (en) Crystalline forms of a pyrrolopyridine-aniline compound
CA3212316A1 (en) Treatment of hidradenitis suppurativa with orismilast
WO2016107879A2 (en) New use of angiotensin ii receptor agonists
EP4185382A1 (en) Methods of treating acute respiratory disorders
JP2020520994A (ja) 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
TW202114991A (zh) 離胺醯氧化酶之二氟鹵烯丙胺碸衍生物抑制劑、製備方法、及其用途
CN108697663A (zh) 在肝病治疗中使用胱天蛋白酶抑制剂的方法
WO2022262854A1 (zh) Cly系列化合物及其制备方法和制备药物的用途
US20260069578A1 (en) Treatment of neutrophilic dermatoses
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
CN117298086B (zh) 索法酮在制备预防和/或治疗nlrp3炎性小体介导的疾病的药物中的应用
TWI910994B (zh) 一種RNA m6A調控劑組合物及其製備方法與應用
CN117479936A (zh) 用奥瑞司特治疗化脓性汗腺炎
JP4477504B2 (ja) 鎮痒剤
CN121943899A (zh) 去氢紫堇鳞茎碱在制备预防和/或治疗动脉粥样硬化药物中的应用
WO2025091065A1 (en) Flavonoid composition
CN116850173A (zh) 一种二氢杨梅素在制备凝血X因子FXa抑制剂的药物中的应用
WO2020190703A1 (en) Methods for wound treatment